1/5/2025, 5:32:02 pm

Buy Ajanta Pharma; target of Rs 3260: Motilal Oswal

Ajanta Pharma reported in-line Q1 performance, with strong Domestic Formulation and US sales offsetting weakness in the anti-malaria business. Branded generics exports faced high base impact, affecting YoY growth. The company continues to strengthen its chronic portfolio positioning. Estimates for FY26/FY27 remain unchanged, with a target price of INR3,260.